Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,764 total articles
Rocket Lab (RKLB) is priced for growth more than profits. With record top-line momentum (Q2 revenue of $234M, ~62% YoY) and a $2.36B backlog, the company’s upcoming Neutron program milestones set the stage for margin expansion and, potentially, sustained profitability. This trade idea lays out a long entry around current levels with a clear stop an…
Legend Biotech's recent in vivo CAR-T readout and manufacturing expansion make its pipeline narrative real. Pair that with improving technicals and manageable financing, and there is a mid-term trade worth considering: enter on weakness, target the $30 area, and protect capital with a below-$18 stop.
Protagonist Therapeutics just cleared a major commercial hurdle with Icotyde (icotrokinra) approval and a $50M milestone payment; the stock still offers upside as the market reprices recurring-revenue potential and waits on rusfertide and other pipeline moves. This trade idea takes a long stance with a 180-trading-day horizon and a clear entry, sto…
Paramount Gold Nevada (PZG) has made measurable permitting progress at Grassy Mountain and picked up federal FAST-41 status, but audited filings with a going concern qualification and only ~$2.6M of cash leave the company exposed if capital markets turn cold. Technicals show an overbought setup while short activity has been meaningful — a setup tha…
Uber's core Mobility and Delivery businesses are producing strong cash flow and improving margins, while Freight and autonomous-vehicle (AV) investments offer asymmetric upside. At a market cap near $160B, P/E ~16.8 and P/FCF ~17, Uber looks priced for steady growth but not for the optionality embedded in robotaxis. I upgrade to a long position wit…
Nvidia is packaging GPUs, financing and software into a repeatable offer that treats AI compute like an investable infrastructure asset. With a $5.35T market cap, industry-leading profitability and a $500B compute-financing initiative, we upgrade NVDA to Buy and recommend a long trade sized for conviction over the next 180 trading days.
Credo Technology is delivering outsized top-line acceleration tied to AI data-center demand. With fiscal revenue now above $1.3B, healthy margins, and a clean balance sheet, the stock still looks like a growth story that has more to run. This trade plan targets a disciplined long entry on a slight pullback and a one-step target above the prior high…
Elanco has a leveraged but improving balance sheet, tangible free cash flow, and a steady cadence of product launches that are starting to show up in results. The market is discounting some execution risk; we view the current pullback as an opportunity to buy a business with $379M of free cash flow, a $11.36B market cap and upside to the 52-week ra…
Elbit Systems (ESLT) has pulled back into the mid-$700s after a run toward $1,016. The business is sitting on a $28.1B order backlog and produced $7.94B in revenue in 2025, and recent margin expansion and an S&P upgrade reduce execution and credit risk. For traders willing to accept defense-sector valuation compression and geopolitical timing risk,…
RadNet couples a recovering imaging business with an aggressive build-out of AI-powered diagnostics through DeepHealth and the Gleamer acquisition. Recent top-line momentum, large addressable markets for clinical AI, and a stretched but defensible valuation create a trade that favors the long side with clearly defined risk controls.
GE Vernova has become a market darling driven by power and electrification tailwinds tied to AI data centers. That said, the stock trades at premium multiples - EV/EBITDA ~86x and P/B >22 - leaving little room for disappointment. We lay out a mid-term (45 trading days) short trade with precise entry, stop, and target and explain the fundamental and…
Planet Labs has the dataset, government customers, and a near-term revenue backlog that justify a bullish long-term stance despite a stretched valuation. This trade idea outlines a practical long entry at current levels, a protective stop, and a target that prices in execution on backlog conversion and margin improvement over the next 180 trading d…
Meta's aggressive open-source strategy for large models is a wedge into developer mindshare and ad inventory optimization. The move risks commoditizing models but also strengthens Meta's platform control and potential monetization across the Family of Apps. We like a mid-term long: entry $599.21, target $720.00, stop $540.00 — horizon 45 trading da…
Global disruptions that keep Russian refined exports effectively sidelined create a multi-month tailwind for U.S. refiners. Marathon Petroleum (MPC) sits at the center of that upside: large scale, integrated refining plus midstream optionality, strong free cash flow, and an attractive valuation on trailing earnings. This trade idea outlines a mid-t…
Merchants Bancorp (MBIN) reported a record asset base in Q2 2026 and continues to draw large institutional interest. With a market cap near $2.5B, a P/B around 1.07 and a 2.4% dividend yield, MBIN looks like a reasonable long candidate for investors willing to weather legal noise and funding-cost volatility. This trade idea lays out an entry at $54…
Ciena is benefitting from hyperscaler optical upgrades tied to the AI infrastructure buildout. Strong top-line momentum, a sizable backlog and robust free cash flow support further upside, but stretched multiples and recent capital markets activity introduce near-term risk. This trade idea frames a mid-term swing entry with explicit entry, target a…
Cheniere just cleared another operational milestone and lifted its forward posture on growth. With Train 6 at Corpus Christi now substantially complete and incremental capacity coming online, the stock trades below its 52-week high and at valuation multiples that the market can reconcile with steady cash flow. This trade idea lays out an entry, sto…
Gilat Satellite Networks offers diversified exposure to the expanding satellite communications market via fixed networks, mobility terminals, and an upcoming strategic acquisition. The stock is actionable from current levels, but the trade depends on execution of Comtech integration, sustained defense orders, and order flow from multi-orbit constel…
Cineverse (CNVS) is a micro-cap streaming and media-technology operator trading at roughly $2.77 with a market cap near $73M. The stock discounts its Matchpoint technology and recently aggregated FAST and SVoD assets. We see asymmetric upside if execution on ad tech and FAST monetization accelerates; trade plan: enter at $2.70, target $5.50, stop $…
Cheniere Energy has just cleared another milestone at Corpus Christi and is entering a multi-year capacity expansion cycle at a time when global LNG supply is under pressure. Fundamentals - contracted cash flows, solid free cash flow generation and visible capacity adds - make a long trade attractive over a 180-trading-day horizon with asymmetric u…
Southern Company ($SO) looks attractively positioned after a steady quarter, a supportive federal nuclear program, and a yield north of 3%. We upgrade to a buy and lay out an actionable trade with entry at $91.00, stop at $86.00, and a target of $100.84 over the next 180 trading days.
Seaport Therapeutics (SPTX) is a clinical-stage neuropsychiatry company trading at roughly $1.4B market cap with a tight float, high short interest and bullish technical momentum. The stock offers development-arbitrage upside if clinical/program milestones or partnership chatter re-rate the valuation; the trade is actionable with a mid-term horizon…
Marvell's sell-off has carved out a tactical buying opportunity. Strong AI-driven demand, healthy free cash flow and a clean balance sheet argue for a mid-term long. This trade plan gives a clear entry ($205.00), stop ($195.00) and target ($260.00) with a 45-trading-day horizon to let AI revenue momentum and technical mean reversion work in your fa…
Pfizer is an income-oriented pharma with a deep late-stage pipeline in obesity and oncology. The stock yields near 6.9%, trades around $26.60 and offers an asymmetric reward if late-stage assets like berobenatide and oncology candidates succeed. We lay out an actionable long trade with entry, stop and target and explain the catalysts, valuation con…
Repsol’s ADR is an actionable long with a clear entry, stop and target. European refining capacity remains tight, supporting margins for companies with integrated refineries. At the same time, Repsol’s push into renewable fuels (notably the Ecoplanta waste-to-methanol contract) gives the stock optionality in the energy transition. Technicals show a…
